|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Sao Paulo |
|---|---|
| Collaborator: |
Cristália Produtos Químicos Farmacêuticos Ltda. |
| Information provided by: | University of Sao Paulo |
| ClinicalTrials.gov Identifier: | NCT00523289 |
Purpose
The purpose of this study is to determine if bupivacaine (75% levobupivacaine plus 25% racemic bupivacaine) with vasoconstrictor is effective and safety as ropivacaine in brachial plexus block for orthopedic surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Injuries, Hand Anesthesia Conduction Anesthetics, Local |
Drug: Bupivacaine Drug: Ropivacaine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
| Estimated Enrollment: | 48 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
B: Active Comparator
Arm number B corresponds to the Bupivacaine group.
|
Drug: Bupivacaine
Dosage: 150mg at once for anesthesia induction
|
|
R: Active Comparator
Arm number R corresponds to the Ropivacaine group.
|
Drug: Ropivacaine
Single dose of ropivacaine, 150mg
|
The intoxication by Bupivacaine is considered life threatening. Currently the most safety local anesthetic in substitution to bupivacaine is ropivacaine, however in Brasil there is a bupivacaine mixture of 75% levobupivacaine plus 25% racemic bupivacaine. The research design is:
Patients involved: 48; age: 18 to 40 years old; both sex; ASA I and II. Surgery: elective upper extremity orthopedic surgery. Anesthesia technique: brachial plexus block. Primary endpoint: cardiovascular safety; analysis by continuous Holter. Secondary endpoint: anesthetic and analgesic efficacy.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Study Chair: | José Otávio C Auler Junior, PhD/Chairman | Hospital das Clínicas - Medicine School of the University of São Paulo |
More Information
| Responsible Party: | University Sao Paulo ( José O.Costa Auler Jr - Full prof.Anesthesiology USP ) |
| Study ID Numbers: | CRT029 |
| Study First Received: | August 29, 2007 |
| Last Updated: | February 18, 2009 |
| ClinicalTrials.gov Identifier: | NCT00523289 History of Changes |
| Health Authority: | Brazil: National Health Surveillance Agency |
|
Ropivacaine Bupivacaine Upper Extremity Local anesthetic |
|
Ropivacaine Physiological Effects of Drugs Wounds and Injuries Disorders of Environmental Origin Anesthetics Central Nervous System Depressants Hand Injuries |
Anesthetics, Local Pharmacologic Actions Sensory System Agents Therapeutic Uses Bupivacaine Peripheral Nervous System Agents Central Nervous System Agents |